Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 8/20 | 0.40 |
| ▸ | PDE5A | O76074 | 4/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | B3GNT2 | Q9NY97 | 9/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE6D | O43924 | 1/20 | 0.33 |
| ▸ | PDE8A | O60658 | 1/20 | 0.33 |
| ▸ | PDE8B | O95263 | 1/20 | 0.33 |
| ▸ | PDE6A | P16499 | 1/20 | 0.33 |
| ▸ | PDE6G | P18545 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE6B | P35913 | 1/20 | 0.33 |
| ▸ | PDE6C | P51160 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591733 | 0.88 | PDE9A (0.55) | PDE9APDE5AB3GNT2PDE2APDE6D | |
| SCHEMBL3597364 | 0.83 | PDE9A (0.40) | PDE9APDE5ASLC2A1PDE2APDE6D | |
| SCHEMBL11997343 | 0.82 | PDE9A (0.39) | PDE9APDE5ASLC2A1 | |
| SCHEMBL3588040 | 0.82 | PDE9A (0.39) | PDE9APDE5ASLC2A1 | |
| SCHEMBL3604582 | 0.80 | PDE9A (0.41) | PDE9A | |
| SCHEMBL3595991 | 0.80 | B3GNT2 (0.39) | PDE9AB3GNT2 | |
| SCHEMBL3596976 | 0.79 | PDE9A (0.35) | PDE9APDE5APDE2APDE6DPDE8A | |
| SCHEMBL3599063 | 0.78 | PDE5A (0.47) | PDE9APDE5AB3GNT2KIF11 | |
| SCHEMBL3606268 | 0.74 | PDE9A (0.59) | PDE9APDE5A | |
| SCHEMBL3602145 | 0.73 | PDE9A (0.48) | PDE9APDE5APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2489667-A1 | Quinoxaline derivative | ASKA Pharmaceutical Co., Ltd. (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | PDE9A, ADCY9, PRMT9 | PDE9A 1/4885PDE5A 8/4885SLC2A1 2429/4885 |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | PDE9A, ADCY9, PDE3A | PDE9A 1/4885PDE5A 6/4885SLC2A1 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.